UK Markets close in 6 hrs 31 mins
  • FTSE 100

    7,101.10
    +19.38 (+0.27%)
     
  • FTSE 250

    23,285.25
    +76.58 (+0.33%)
     
  • AIM

    1,257.50
    -0.11 (-0.01%)
     
  • GBP/EUR

    1.1706
    +0.0017 (+0.15%)
     
  • GBP/USD

    1.3911
    +0.0028 (+0.1989%)
     
  • BTC-GBP

    27,728.09
    -809.81 (-2.84%)
     
  • CMC Crypto 200

    936.20
    -24.70 (-2.57%)
     
  • S&P 500

    4,387.16
    -8.10 (-0.18%)
     
  • DOW

    34,838.16
    -97.31 (-0.28%)
     
  • CRUDE OIL

    71.62
    +0.36 (+0.51%)
     
  • GOLD FUTURES

    1,814.10
    -8.10 (-0.44%)
     
  • NIKKEI 225

    27,641.83
    -139.19 (-0.50%)
     
  • HANG SENG

    26,194.82
    -40.98 (-0.16%)
     
  • DAX

    15,572.99
    +4.26 (+0.03%)
     
  • CAC 40

    6,726.77
    +50.87 (+0.76%)
     

What’s going on with the Sareum Holdings share price?

·3-min read
Businessman using calculator next to laptop

The Sareum Holdings (LSE: SAR) share price has exploded over the past 12 months. The stock is up 1,600% since mid-June last year. In the past week, the rally has only accelerated. Since the middle of last week, shares in the company have added 110%.

Sareum Holdings share price

It would appear investors have been buying into this business as part of the coronavirus-related trade. Over the past 18 months, companies that have been engaged in developing treatments or tests for coronavirus have attracted significant investor attention.

Sareum is primarily a specialist drug development company delivering targeted small molecule therapeutics to improve cancer and autoimmune disease treatment. One of its treatments is SDC-1802, a novel selective TYK2/JAK1 inhibitor. Studies have shown this treatment significantly reduces tumour growth in specific cancers.

However, it also has the potential to help severe Covid-19 patients. To help investigate the treatment’s impact on severe coronavirus cases, the company has received grant funding from the UK government. It’s currently studying the therapeutic potential of the treatment and is expected to report on the initial six-month study in the middle of 2021.

If the results of this study are favourable, the company may be able to access more government funding, which could help progress the drug through clinical trials.

It seems to me that SDC-1802’s coronavirus treating potential is the main reason why the Sareum Holdings share price has performed so strongly over the past 12 months. Especially as the company’s other cancer treatments are still in their early stages of development.

While it does appear as if the business has potential, I think there’s a lot that could go wrong between now and the commercialisation of any of its products. All of Sareum’s treatments are still in their early stages of development. None have reached the clinical trial stage yet, which is concerning.

At the same time, the company is cash poor. It has been issuing new shares recently to raise additional funding. As the firm moves forward with its drug development plans, it could require further cash infusions.

Two outcomes

Overall, I can see two outcomes for the business. If the company’s cancer treatments are effective, they could generate hundreds of millions, or billions, of pounds in sales. But that’s the best-case scenario, and it could be years before any of the treatments are on the market.

In the worst-case scenario, the company could run out of money. This would be a terrible development for the Sareum Holdings share price.

Considering these two scenarios, I’m not a buyer of the stock today. I think this investment is incredibly speculative, and there’s far more that could go wrong than right for the enterprise.

The vast majority of new drugs never make it through the development pipeline. Most fail before they get to market. Sareum may be able to buck the trend, but it’s far from certain at this point.

The post What’s going on with the Sareum Holdings share price? appeared first on The Motley Fool UK.

More reading

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Motley Fool UK 2021

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting